" class="no-js "lang="en-US"> National Cancer Center Japan - Medtech Alert
Tuesday, June 10, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
National Cancer Center Japan | Pharmtech Focus

National Cancer Center Japan

About National Cancer Center Japan

National Cancer Center Japan
National Cancer Center was established in 1962 by the Japanese Government as the first national hospital and research institute specializing in cancer patient management and basic and translational research of cancer. It is one of the two hospitals of the National Cancer Center, Japan, and is supported by the Ministry of Health, Labor and Welfare of the Japanese Government

Related Story

Diseases

 New Phase III Data Show Novartis Tislelizumab Significantly Extended Median Overall Survival by More Than 6 Months in First-line Advanced Esophageal Cancer in Combination With Chemotherapy | Pharmtech Focus

New Phase III Data Show Novartis Tislelizumab Significantly Extended Median Overall Survival by More Than 6 Months in First-line Advanced Esophageal Cancer in Combination With Chemotherapy

July 4 2022

Today Novartis announced results from the Phase III RATIONALE 306 trial showing tislelizumab plus chemotherapy […]